Keyphrases
Receptor Tyrosine Kinase
100%
Acute Myeloid Leukemia
100%
Activating Receptors
100%
Platelet-derived Growth Factor Receptor (PDGFR)
100%
AML1-ETO
100%
Platelet-derived Growth factor-BB (PDGF-BB)
33%
Hematopoietic Cells
11%
Imatinib
11%
Novel Therapeutics
11%
Murine Bone Marrow
11%
Survival Benefit
11%
Leukemia
11%
Leukemogenesis
11%
Histone Deacetylase Inhibitor (HDACi)
11%
DNA Binding
11%
Tyrosine Kinase Inhibitor
11%
Pharmacological Inhibitors
11%
Runt-related Transcription Factor 1 (RUNX1)
11%
Transplantable
11%
Myeloproliferative Neoplasms
11%
Activating mutation
11%
Kinase mutation
11%
Additional mutations
11%
Hydroxamic Acid
11%
Co-repressor Complex
11%
Histone Deacetylases
11%
Histone Deacetylase Activity
11%
Syngeneic Mice
11%
Nuclear Corepressor
11%
Fusion Oncogene
11%
Trichostatin A
11%
Imatinib Mesylate
11%
Biochemistry, Genetics and Molecular Biology
Receptor Tyrosine Kinase
100%
Myeloid
100%
Histone Deacetylase
33%
Platelet Derived Growth Factor Receptor Beta
33%
Imatinib
22%
Maturation
11%
Gene Fusion
11%
DNA Binding
11%
Corepressor
11%
Tyrosine Kinase Inhibitor
11%
Syngenic
11%
RUNX1
11%
Trichostatin A
11%
Hematopoietic Cell
11%
Neuroscience
Receptor Tyrosine Kinase
100%
Myeloid
100%
Histone Deacetylase
22%
Imatinib
22%
DNA Binding
11%
Tyrosine Kinase Inhibitor
11%
RUNX1
11%
Gene Fusion
11%
Corepressor
11%
Histone Deacetylase Inhibitor
11%
Trichostatin A
11%
Hydroxamic Acid
11%
Hematopoietic Cell
11%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase
100%
Acute Myeloid Leukemia
100%
Imatinib
22%
Histone Deacetylase
22%
Disease
11%
Leukemia
11%
Leukemogenesis
11%
Histone Deacetylase Inhibitor
11%
Protein Tyrosine Kinase Inhibitor
11%
Hydroxamic Acid
11%
Myeloproliferative Disorder
11%
Trichostatin A
11%
Immunology and Microbiology
Myeloid
100%
PDGFRB
33%
Hematopoietic Cell
11%
DNA Binding
11%
Syngenic
11%
Maturation
11%
Gene Fusion
11%